Lymphocyte Activating Gene 3 (LAG3) Antibody Market Report 2025

The lymphocyte activating gene 3 (LAG3) antibody market size has grown rapidly in recent years. It will grow from $0.7 billion in 2024 to $0.8 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth observed during the historic period can be attributed to the rising prevalence of cancer, increasing demand for immune checkpoint inhibitors, greater adoption of targeted therapies, expanding applications in immuno-oncology, and increased government funding for cancer research.

The lymphocyte activating gene 3 (LAG3) antibody market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2029 at a compound annual growth rate (CAGR) of 13.9%. The growth projected for the forecast period can be attributed to an expanding pipeline of lymphocyte-activating 3 (LAG3) antibody candidates, increasing clinical trials and regulatory approvals, rising collaboration among biotech companies, broader applications in autoimmune disorders, and growing global healthcare spending. Key trends during this period include advancements in antibody engineering, sustained investments in research and development, the creation of novel LAG3-based bispecific and trispecific antibodies, the integration of artificial intelligence in antibody discovery, and innovations in drug delivery technologies.

The increasing incidence of cancer is expected to drive the growth of the lymphocyte activating gene 3 (LAG3) antibody market in the coming years. Cancer incidence refers to the number of new cancer cases identified within a specific population over a defined period. This rise is largely attributed to lifestyle-related risk factors such as unhealthy diets, smoking, alcohol consumption, and exposure to environmental pollutants, all of which elevate the likelihood of developing various cancers. LAG3 antibodies support cancer treatment by restoring the function of exhausted T cells, thereby enhancing the immune system’s ability to target tumors. They improve treatment outcomes by strengthening anti-tumor responses, offering new therapeutic hope for patients with advanced cancers. For example, in July 2024, the Australian Institute of Health and Welfare reported that cancer diagnoses in Australia reached 160,570 cases in 2022, an increase of 3,789 cases from 156,781 in 2021. Consequently, the rising incidence of cancer is propelling the growth of the LAG3 antibody market.

Leading companies in the LAG3 antibody market are focusing on innovative therapies such as fixed-dose dual immunotherapy to enhance anti-tumor immune responses, extend treatment durability, and broaden options for patients with advanced cancers. Fixed-dose dual immunotherapy combines two immunotherapy drugs into a single, pre-set dosage to improve efficacy, simplify administration, and reduce variability in patient responses. For instance, in March 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, received U.S. FDA approval for Opdualag, a fixed-dose combination of nivolumab (a PD-1 blocking antibody) and relatlimab-rmbw (an LAG3 blocking antibody), for the treatment of adult and pediatric patients aged 12 years or older with unresectable or metastatic melanoma. This marked the first regulatory approval for an LAG3-blocking antibody in combination therapy, representing a significant milestone in the immuno-oncology field.

In June 2023, Chime Biologics Limited, a China-based contract development and manufacturing organization (CDMO), partnered with Leads Biolabs Inc. and BeiGene Ltd. to accelerate the development and production of innovative biologics, including monoclonal and bispecific antibody therapies. This collaboration aims to advance clinical pipelines and expand access to next-generation cancer immunotherapies. Leads Biolabs, based in China, focuses on developing LAG3 antibodies for cancer immunotherapy, while BeiGene, a US-based biotechnology company, develops LAG3 antibodies to enhance immune checkpoint inhibition.

Major players in the lymphocyte activating gene 3 (lag3) antibody market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Ono Pharmaceutical Co. Ltd., Xencor Inc., Innovent Biologics Inc., Zai Lab Limited, MacroGenics Inc., Akeso Inc., Agenus Inc., Alphamab Oncology, Adaptimmune Therapeutics plc, AnaptysBio Inc., Crescendo Biologics Ltd., EpimAb Biotherapeutics Inc., Shanghai Henlius Biotech Inc., Immutep Limited.

North America was the largest region in the lymphocyte activating gene 3 (LAG3) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lymphocyte activating gene 3 (LAG3) antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lymphocyte activating gene 3 (LAG3) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Lymphocyte-activating gene 3 (LAG3) antibodies are a class of therapeutic monoclonal antibodies that target the LAG-3 protein, an immune checkpoint receptor found on activated T cells. By blocking LAG-3, these antibodies aim to restore T cell function and enhance immune responses, making them valuable in cancer immunotherapy and the treatment of chronic infections by overcoming T cell exhaustion.

The primary types of LAG3 antibodies include monoclonal, polyclonal, and bispecific antibodies. Monoclonal antibodies are lab-engineered molecules designed to specifically bind a single target antigen, aiding the immune system in detecting and neutralizing harmful pathogens or diseased cells. These antibodies are available in different drug classes, such as monotherapy and combination therapy, and act through various mechanisms, including immune checkpoint inhibition, immunomodulatory activity, and co-stimulatory signaling. They are applied in areas like cancer immunotherapy, autoimmune disorders, and infectious diseases, with key end users including pharmaceutical and biotechnology companies, academic research institutions, and diagnostic laboratories.

The lymphocyte activating gene 3 (LAG3) antibody market research report is one of a series of new reports that provides lymphocyte activating gene 3 (LAG3) antibody market statistics, including the lymphocyte activating gene 3 (LAG3) antibody industry global market size, regional shares, competitors with the lymphocyte activating gene 3 (LAG3) antibody market share, detailed lymphocyte activating gene 3 (LAG3) antibody market segments, market trends, and opportunities, and any further data you may need to thrive in the lymphocyte activating gene 3 (LAG3) antibody industry. This lymphocyte activating gene 3 (LAG3) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lymphocyte activating gene 3 (LAG3) antibody market consists of sales of relatlimab, favezelimab, eftilagimod alpha, biosimilars, antibody-drug conjugates, and combination therapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.